NasdaqCM - Nasdaq Real Time Price USD

Forte Biosciences, Inc. (FBRX)

Compare

5.25

-0.64

(-10.87%)

At close: April 11 at 4:00:01 PM EDT

5.25

0.00

(0.00%)

After hours: April 11 at 4:05:10 PM EDT

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Simply Wall St. 11 days ago

FBRX
-10.87%
Forte Biosciences, Inc. Announces Results and Provides Clinical Update

DALLAS, March 31, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced full year 2024 results and provides a clinical update.

Business Wire 12 days ago

FBRX
-10.87%
One Forte Biosciences Insider Raised Stake By 273% In Previous Year

Looking at Forte Biosciences, Inc.'s ( NASDAQ:FBRX ) insider transactions over the last year, we can see that insiders...

Simply Wall St. last month

FBRX
-10.87%
Forte Biosciences to Host R&D Day December 3, 2024

DALLAS, November 25, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day on December 3, 2024 at 4:30 p.m. ET.

Business Wire 4 months ago

FBRX
-10.87%
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

DALLAS, November 20, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102.

Business Wire 4 months ago

FBRX
-10.87%
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

DALLAS, November 14, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024 results and provided a business update.

Business Wire 4 months ago

FBRX
-10.87%
Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested

These are the upcoming stock splits for the week of August 26 to August 30, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate). In t

TipRanks 7 months ago

FBRX
-10.87%
GDEV

GDEVW
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

DALLAS, August 14, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced second quarter 2024 results and provided a business update.

Business Wire 7 months ago

FBRX
-10.87%
Companies Like Forte Biosciences (NASDAQ:FBRX) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 10 months ago

FBRX
-10.87%
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

DALLAS, May 17, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules.

Business Wire 10 months ago

FBRX
-10.87%
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

DALLAS, May 13, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update.

Business Wire 10 months ago

FBRX
-10.87%

Performance Overview

Return	FBRX	S&P 500 (^GSPC)
YTD	-76.88%	-8.81%
1-Year	-70.83%	+3.16%
3-Year	-84.44%	+21.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Forte Biosciences, Inc. (FBRX)

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

One Forte Biosciences Insider Raised Stake By 273% In Previous Year

Forte Biosciences to Host R&D Day December 3, 2024

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Companies Like Forte Biosciences (NASDAQ:FBRX) Could Be Quite Risky

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Performance Overview